AtriCure, Inc. (ATRC) News
Follow AtriCure, Inc. (ATRC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 24 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Biotech Stocks At 52-Week Highs - TKNO, MRNA, ATRC, ILMN
SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on September 23, 2026, driven by key catalysts such as positive quarterly reports or results from clinical trials.Alpha Teknova Inc. (TKNO)Alpha T
NEWS | Sep 24, 2026, 09:42 AM UTC
L
Biotech Stocks At 52-Week Highs - NUTX +8%, IOVA +7%, ATRC, CNC, CON
WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on September 15, 2026, driven by the gain on certain clinical or financial results.Nutex Health Inc. (NUTX)Nutex Health functions as a healthcare
EARNINGS | Sep 15, 2026, 07:40 AM UTC
L
ATRC says pain management and clinical trials are ahead of plan
Management said progress is ahead of long-term targets, with pain management growth and clinical trials advancing faster than planned, supported by new product launches, innovation investment, market expansion, and quali
EQUITY | Sep 08, 2026, 03:34 PM UTC
M
ATRC says revenue and profitability are ahead of long-term targets
ATRC says revenue and profitability are ahead of long-term targets, citing strong pain management growth, clinical trial progress and product innovation. It also highlights LEAPS and BoxX-NoAF advancing ahead of schedule
EQUITY | Sep 08, 2026, 03:02 PM UTC
L
NexPoint Residential, Amerisafe, Cogent exit S&P SmallCap 600
NexPoint Residential Trust, Amerisafe, and Cogent Communications will leave the S&P SmallCap 600.
EQUITY | Sep 04, 2026, 09:43 PM UTC
M
S&P SmallCap 600 to drop Shenandoah, Verra, Matthews, Franklin BSP
Shenandoah Telecommunications, Verra Mobility, Matthews International and Franklin BSP Realty to leave the S&P SmallCap 600.
EQUITY | Sep 04, 2026, 09:41 PM UTC
L
AXTI, ARQT, ATRC and EAT to join S&P SmallCap 600
AXTI, ARQT, ATRC and EAT are set to join the S&P SmallCap 600 index.
EQUITY | Sep 04, 2026, 09:38 PM UTC
L
Needham maintains Buy rating on AtriCure
Needham maintained a Buy rating on AtriCure (ATRC), according to Benzinga ratings actions.
EQUITY | Sep 02, 2026, 10:12 AM UTC
L
AtriCure maintained at Overweight by Piper Sandler
Piper Sandler maintains an Overweight stance on AtriCure.
EQUITY | Aug 27, 2026, 04:53 PM UTC
L
ATRC price target raised to $55; Buy maintained by BTIG
ATRC price target is raised from $45 to $55 while a Buy rating is maintained at BTIG, per Hammerstone MarketTalk.
EQUITY | Aug 24, 2026, 01:14 PM UTC
H
Top 3 Health Care Stocks That May Implode This Month
As of July 29, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a
EARNINGS | Jul 29, 2026, 12:45 PM UTC
L
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
EQUITY | Jul 28, 2026, 11:47 AM UTC
L
ATRC Reiterate Outperform and $52 PT after Q2 results beat @ Citizens
ATRC Reiterate Outperform and $52 PT after Q2 results beat @ Citizens
EQUITY | Jul 24, 2026, 12:10 PM UTC
L
AtriCure targets $602M-$610M 2026 revenue while raising adjusted EBITDA outlook to $85M-$89M
AtriCure targets $602M-$610M 2026 revenue while raising adjusted EBITDA outlook to $85M-$89M
EQUITY | Jul 24, 2026, 01:45 AM UTC
H
AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript
AtriCure (NASDAQ: ATRC ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you APIs. For real-tim
EARNINGS | Jul 23, 2026, 09:39 PM UTC
H
among movers from the earnings calendar after the close gainers INTC +9.4%, JAKK +7.8%, WKC +7.1%, EW +6.8%, UVE +6.2%, ATRC +3.0%, SSNC +2.
among movers from the earnings calendar after the close gainers INTC +9.4%, JAKK +7.8%, WKC +7.1%, EW +6.8%, UVE +6.2%, ATRC +3.0%, SSNC +2.9%, KN +2.2%, KNSL +2.2%, DLR +2.1%, AMTB +2.0%, ENVA +1.9%, OVV +1.0%, ORC +0.8
EARNINGS | Jul 23, 2026, 08:38 PM UTC
L
ITNC +12.8%, THC +10.5%, JAKK +5.6%, WKC +4.4%, SAP +4.4%, EW +4.3%, ATRC +3%, RNG +3%, SAM +3.1% after results
ITNC +12.8%, THC +10.5%, JAKK +5.6%, WKC +4.4%, SAP +4.4%, EW +4.3%, ATRC +3%, RNG +3%, SAM +3.1% after results
EQUITY | Jul 23, 2026, 08:21 PM UTC
L
ATRC Q2 adj EPS $0.18 vs est $0.00, adj EBITDA $27.3Mm vs est $19.94Mm on revs $153.6Mm vs est $151.8Mm, gr mgn 77.2%; guides FY revs $602-6
ATRC Q2 adj EPS $0.18 vs est $0.00, adj EBITDA $27.3Mm vs est $19.94Mm on revs $153.6Mm vs est $151.8Mm, gr mgn 77.2%; guides FY revs $602-610Mm vs est $604.99Mm, adj EBITDA $85-89Mm vs est $80.53Mm and adj EPS $0.24-0.3
EARNINGS | Jul 23, 2026, 08:07 PM UTC
L
AtriCure sees FY26 adjusted EPS 24c-32c, consensus 12c
Narrows FY26 revenue view...
EARNINGS | Jul 23, 2026, 08:06 PM UTC
L
AtriCure reports Q2 adjusted EPS 18c, consensus 2c
Reports Q2 revenue...
EARNINGS | Jul 23, 2026, 08:05 PM UTC
L
SCHL -5.7%, ATRC -1.3%, COLB -1.1% after results
SCHL -5.7%, ATRC -1.3%, COLB -1.1% after results
EQUITY | Jul 23, 2026, 08:03 PM UTC
H
ATRC Atricure RESULTS: Q2, Q2 ADJ EPS $0.18 vs. EST $0, Q2 REV $153.6M vs. EST $151.8M, Q2 gross profit $118.6M, Q2 ADJ EBITDA $27.3M vs. ES
ATRC Atricure RESULTS: Q2, Q2 ADJ EPS $0.18 vs. EST $0, Q2 REV $153.6M vs. EST $151.8M, Q2 gross profit $118.6M, Q2 ADJ EBITDA $27.3M vs. EST $19.9M, Q2 gross margin 77.2%, Q2 Operating Income $9.7M, Atricure Earnings No
RATES | Jul 23, 2026, 08:02 PM UTC
H
AtriCure Raises FY2026 Adj EPS Guidance from $0.00-$0.04 to $0.24-$0.32 vs $0.06 Est; Raises FY2026 Sales Guidance from $600.000M-$610.000M
AtriCure (NASDAQ: ATRC ) raises FY2026 Adj EPS guidance from $0.00-$0.04 to $0.24-$0.32 vs $0.06 analyst estimate. Raises FY2026 sales outlook from $600.000 million-$610.000 million to $602.000 million-$610.000 million v
EARNINGS | Jul 23, 2026, 08:02 PM UTC
H
earnings calendar: • earnings before the open: aal aci alle amal amp argx bfh bpop bx civb clf cmcsa coco cx dgx dov Dow fcnca fcx fsv hban
earnings calendar: • earnings before the open: aal aci alle amal amp argx bfh bpop bx civb clf cmcsa coco cx dgx dov Dow fcnca fcx fsv hban hog hon ibcp imax infy laz lmt mbly ndaq nok nsc nvcr orio pcg Pool r rop RTX sn
EARNINGS | Jul 23, 2026, 10:54 AM UTC